To investigate whether the replication of rSARS-CoV-2 nsp1:KH-AA could be rescued in an IFN competent cell line, AAT cells were treated pre- and post-infection with ruxolitinib, an inhibitor of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. This evidence concerns the gene SH2D3A and infection.